These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 27195527)

  • 1. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.
    Olagunju A; Bolaji O; Neary M; Back D; Khoo S; Owen A
    Pharmacogenet Genomics; 2016 Aug; 26(8):381-9. PubMed ID: 27195527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
    Vardhanabhuti S; Acosta EP; Ribaudo HJ; Severe P; Lalloo U; Kumarasamy N; Taulo F; Kabanda J; Oneko O; Ive P; Sambarey P; Chan ES; Hitti J; Hong F; McMahon D; Haas DW;
    J Infect Dis; 2013 Aug; 208(4):662-71. PubMed ID: 23687222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
    Olagunju A; Bolaji O; Amara A; Else L; Okafor O; Adejuyigbe E; Oyigboja J; Back D; Khoo S; Owen A
    Clin Pharmacol Ther; 2015 Mar; 97(3):298-306. PubMed ID: 25669165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
    Bienczak A; Cook A; Wiesner L; Mulenga V; Kityo C; Kekitiinwa A; Walker AS; Owen A; Gibb DM; Burger D; McIlleron H; Denti P
    J Antimicrob Chemother; 2017 Jan; 72(1):190-199. PubMed ID: 27707991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
    Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
    Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
    Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    Neary M; Chappell CA; Scarsi KK; Nakalema S; Matovu J; Achilles SL; Chen BA; Siccardi M; Owen A; Lamorde M
    J Antimicrob Chemother; 2019 Oct; 74(10):3003-3010. PubMed ID: 31299074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
    Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
    Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.
    Lehr T; Yuan J; Hall D; Zimdahl-Gelling H; Schaefer HG; Staab A; MacGregor TR; Jayadev S
    Pharmacogenet Genomics; 2011 Nov; 21(11):721-30. PubMed ID: 21860339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
    Lamorde M; Byakika-Kibwika P; Okaba-Kayom V; Flaherty JP; Boffito M; Namakula R; Ryan M; Nakabiito C; Back DJ; Khoo S; Merry C; Scarsi KK
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):345-50. PubMed ID: 20622674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
    Fayet-Mello A; Buclin T; Guignard N; Cruchon S; Cavassini M; Grawe C; Gremlich E; Popp KA; Schmid F; Eap CB; Telenti A; Biollaz J; Decosterd LA; Martinez de Tejada B; ;
    Antivir Ther; 2013; 18(2):171-82. PubMed ID: 22914504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.
    Eniayewu O; Azuka U; Ogah J; Adejuyigbe E; Bolaji O; Olagunju A
    Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38859656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.